biotech / news / / USA TODAY
Moderna's MRNA.O mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial.
Moderna's mRNA flu vaccine was 26.6% more effective than GSK's standard-dose shot in a large trial.
KEY POINTS
- The FDA reversed its initial rejection and now reviews Moderna's amended flu vaccine application.
- If approved, this shot would be the first U.S. mRNA-based seasonal flu vaccine.
- Moderna must conduct an additional study in adults 65+ as a condition of FDA review acceptance.
- Regulatory reviews for Moderna's flu shot are ongoing in the EU, Canada, and Australia.
COMPANIES
Summarized by Newsio from USA TODAY. How we summarize →